Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
February 01 2023 - 7:00AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that Chen Schor, President
and Chief Executive Officer, will participate in a fireside chat at
the 2023 Guggenheim Oncology Conference being held from February
8-9, 2023.
Details of the event are as follows: Date: Thursday, February 9,
2023 Time: 2:10 p.m. ET
The live audio webcast can be accessed on the Investors section
of Adicet Bio’s website at http://www.adicetbio.com. An archived
replay will be available for 30 days following the
presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and adaptors (CAds), to enhance selective tumor targeting and
facilitate innate and adaptive anti-tumor immune response for
durable activity in patients. For more information, please visit
our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230130005648/en/
Adicet Bio., Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024